Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMCXNIP)

Drug Name
MORAb-009 Drug Info
Synonyms Amatuximab
Indication
Disease Entry ICD 11 Status REF
Mesothelioma 2C51.2 Phase 2 [1]
Cross-matching ID
TTD Drug ID
DMCXNIP

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Mesothelin (MSLN) TT4RXME MSLN_HUMAN Not Available [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Mesothelin (MSLN) DTT MSLN -0.515 2.233 -0.152 0
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Mesothelioma
ICD Disease Classification 2C51.2
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Mesothelin (MSLN) DTT MSLN 2.86E-20 3.98 6.12
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7750).
2 Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma. Clin Cancer Res. 2014 Dec 1;20(23):5927-36.